Design: Prospective observational population pharmacokinetic study
Population: 77 adults on ruxolitinib; 221 steady-state concentrations
Primary outcome: Clearance variability and covariates; exposure–response
Effect: Strong CYP3A4 inhibitors cut clearance 39%; trough ×2.9, AUC ×1.7

This prospective observational study analysed 221 steady-state ruxolitinib concentrations from 77 adults treated in routine practice in Switzerland for haematological malignancies and immune-mediated diseases, using population pharmacokinetic modelling.

Between-patient variability in clearance was large (45%). Strong CYP3A4 inhibitors, or dual CYP2C9/CYP3A4 inhibitors, reduced clearance by 39%; at 10 mg twice daily, simulations showed median trough concentration rose 2.9-fold and 24-hour exposure 1.7-fold. No exposure–efficacy relationship was found, but higher exposure was associated with more toxicity (P about 0.02–0.03).

The interacting drugs are common in these patients — azole antifungals such as posaconazole and voriconazole after transplant are the obvious example. The label advises dose reduction with strong inhibitors; these data show the size of the effect in real patients and support doing it, with therapeutic drug monitoring where available.

Reduce the ruxolitinib dose when starting a strong CYP3A4 inhibitor such as posaconazole, voriconazole or clarithromycin.
Treat fluconazole at higher doses as a dual CYP2C9/CYP3A4 inhibitor with a similar effect.
Watch for cytopenias and infection after adding an interacting drug.
Consider ruxolitinib level monitoring where available, given 45% variability between patients.
Re-escalate the dose when the inhibitor is stopped.

Why it matters

It turns a label warning into a measured effect size that justifies routine dose adjustment.

The statistics, in plain English

A 45% coefficient of variation in clearance means two patients on the same dose can have very different blood levels. The toxicity association (P about 0.02–0.03) is exploratory in 77 patients; it supports caution, not a specific target level.